查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1549435

印度的學名藥市場評估:各用途，各類型，不同品牌，各給藥途徑，各流通管道，各地區，機會，預測(2018年度～2032年度)

India Generic Drugs Market Assessment, By Application, By Type, By Brand, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, FY2018-FY2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 122 Pages | 商品交期: 3-5個工作天內

價格

印度仿製藥市場規模預計將從 2024 財年的 137.1 億美元增至 2032 財年的 259.4 億美元，預計 2025 財年至 2032 財年的複合年增長率為 8.29%。市場成長得益於政府推出的支持性政策和措施、慢性病盛行率的上升以及主要市場參與者增加投資的支持。人們對仿製藥相關各種益處的認識不斷提高，也推動了印度對仿製藥的需求。仿製藥透過確保具有成本效益的治療來幫助滿足國家的醫療保健需求。

市場成長也受到該國市場領導者推出新藥的支持。 2023年1月，太陽製藥工業有限公司在印度推出了輝瑞乳癌藥物palbociclib的仿製藥。該公司的印度專利到期後，仿製藥就有可能進入市場。該新藥的上市將確保該藥物在印度的供應，提高患者的便利性，並為對抗印度最常見的癌症之一乳癌做出貢獻。根據全球癌症觀察站 (GCO) 估計，2022 年印度將有約 98,337 名女性死於乳癌。

主要市場參與者也積極投資複雜仿製藥的開發，並且越來越注重研發活動。對仿製藥的嚴格監管可確保患者能夠獲得並維持有效的治療解決方案，這對於對抗需要頻繁用藥的慢性和終身疾病至關重要。

慢性病患者增加帶動市場需求

該國糖尿病、癌症、神經血管疾病和心血管疾病等各種慢性疾病的盛行率不斷上升，正在為市場創造利潤豐厚的成長機會。根據世界衛生組織（WHO）估計，印度18歲以上的人中約有7,700萬人患有第2型糖尿病，其中2,500萬人處於罹患糖尿病的高風險之中。越來越多的此類疾病患者，以及生活方式的改變和人口老化，需要醫療保健專業人員和患者都青睞的具有成本效益的長期藥物，以支持市場成長。

政府加大力度支持市場擴張

越來越多地推出支持性政策和措施來促進製藥業的研發活動，正在擴大印度的仿製藥市場規模。 2023年9月，國家醫藥醫療技術研發創新政策出台，支持全球製藥業轉型為高價值、高產量企業。該政策旨在激勵國內外企業增加某些高價值產品的生產和投資，例如複雜仿製藥、專利到期藥物和生物製藥。此類舉措預計將支持複雜仿製藥的開發並對市場擴張產生積極影響。

心血管應用佔主要市佔率

印度心血管疾病患者數量不斷增加，這推動了印度仿製藥市場的需求。根據2022年2月發表在《臨床流行病學與全球健康》的一篇論文，印度45歲以上成年人自報的心血管疾病盛行率為29.4%。該國心血管疾病患者數量的增加可歸因於缺乏運動、高膽固醇和糖尿病。這種增長增加了對心血管治療仿製藥的需求。由於其成本效益，仿製藥替代對於患者和衛生系統都具有潛在的重要意義。此外，這種替代提高了藥品支出的價值。

本報告針對印度仿製藥市場進行研究和分析，提供市場規模和預測、市場動態、主要參與者的現狀和前景等。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 印度的學名藥市場預測(2018年度～2032年度)

  • 市場規模的分析與預測
    • 金額
    • 數量
  • 市場佔有率分析與預測
    • 各用途
    • 各類型
    • 不同品牌
    • 各給藥途徑
    • 各流通管道
    • 各地區
    • 市場佔有率分析:各企業(金額)(前五名公司和其他 - 2024年度)
  • 市場地圖分析(2024年度)
    • 各用途
    • 各類型
    • 不同品牌
    • 各給藥途徑
    • 各流通管道
    • 各地區

第5章 供需分析

第6章 進口和出口的分析

第7章 價值鏈分析

第8章 波特的五力分析

第9章 大環境分析

第10章 價格分析

第11章 市場動態

  • 推動市場要素
  • 市場課題

第12章 市場趨勢與發展

第13章 法規結構和革新

  • 生物有效性/生物學的同等性實驗
  • 法規當局的認證

第14章 專利的有效期限

第15章 案例研究

第16章 競爭情形

  • 市場領導者前五名公司的競爭矩陣
  • 前五名公司的SWOT分析
  • 主要企業前十大企業的形勢
    • Aurobindo Pharmaceuticals
    • Sun Pharmaceutical Industries Ltd.
    • Cipla Ltd.
    • Dr. Reddy's Laboratories
    • Teva Pharmaceuticals Industries Ltd.
    • Lupin Ltd.
    • Zydus Group
    • Novartis AG
    • Fresenius Kabi India Pvt. Ltd.
    • Viatris Inc.

第17章 策略性推薦

第18章 本公司相關資料，免責聲明

Product Code: MX11866

India generic drugs market is projected to witness a CAGR of 8.29% during the forecast period FY2025-FY2032, growing from USD 13.71 billion in FY2024 to USD 25.94 billion in FY2032. The market's growth is supported by the introduction of supportive government policies and initiatives, the increasing prevalence of chronic diseases, and rising investments by the key market players. The growing awareness about the various advantages associated with generic drugs is also propelling the demand for generic drugs in India. Generic drugs aid in addressing the healthcare requirements of the country's population by ensuring the availability of cost-effective treatments.

The growth of the market is also supported by novel drug launches by the key players of the market in the country. In January 2023, Sun Pharmaceutical Industries Ltd. launched the generic version of palbociclib, Pfizer Inc.'s breast cancer medicine, in India. The entry of the generic version of the drug was possible after the expiration of the company's Indian patent on the product. This launch ensured the affordability of the drug in the country, aiding in improving patient accessibility and combating breast cancer, which is one of the most common forms of cancer in India. As per the estimates of the Global Cancer Observatory (GCO), India had approximately 98,337 female deaths related to breast cancer in 2022.

Additionally, the key market players are actively investing towards the development of complex generic drugs and increasingly focusing on research and development activities. The stringent regulations for generic drugs ensure the availability of effective therapeutic solutions while maintaining their affordability, which is essential for combating chronic and lifelong diseases in which the patient requires frequent doses of medications.

Rising Cases of Chronic Diseases Boosts Market Demand

The increasing incidence of various chronic diseases in the country, including diabetes, cancer, neurovascular diseases, and cardiovascular diseases, among others, are providing lucrative growth opportunities to the market. The World Health Organization (WHO) estimates that approximately 77 million individuals above the age of 18 in India suffer from type 2 diabetes, and 25 million are at a greater risk of developing diabetes. The rising cases of such diseases, coupled with changing lifestyles and the expansion of the aging population, are propelling the requirement for long-term medications that are cost-effective and are preferred by both healthcare providers and patients, supporting the India generic drugs market growth.

Increasing Government Initiatives Support Market Expansion

The increasing launch of supportive policies and initiatives to promote research and development activities in the pharmaceutical sector is boosting India's generic drugs market size. In September 2023, the National Policy on Research and Development and Innovation in Pharma-MedTech Sector was launched to support the country's transformation into a high-value and volume player in the global pharmaceuticals industry. The policy aims to incentivize the domestic and global players to enhance production and investments in specific high-value products, including complex generic drugs, drugs nearing patent expiration, and biopharmaceuticals, among others. Such initiatives are expected to support the development of complex generic drugs and positively influence the market's expansion.

Cardiovascular Applications Hold Significant Market Share

The rising cases of cardiovascular diseases in the country are bolstering the India generic drugs market demand. According to an article published in Clinical Epidemiology and Global Health in February 2022, the self-reported prevalence of cardiovascular diseases in India was 29.4% for adults aged 45 and above. The increasing number of cases of cardiovascular diseases in the country can be attributed to a lack of physical activity, high cholesterol, and diabetes. This increase is propelling the requirement for generic versions of cardiovascular drugs as the generic substitutions are potentially important for both patients and the healthcare system due to their cost-effectiveness. Furthermore, the substitution also improves the value of pharmaceutical spending.

Meanwhile, diabetology is expected to witness significant growth in the coming years. The rising cases of diabetes in India can be attributed to the profound lifestyle and environmental changes witnessed by the population. These changes, including rising per capita spending, industrialization, booming culture of eating out, and migration to urban cities, are contributing to the increasing prevalence of diabetes.

Retail Pharmacies Account for Major Market Share

The strong presence of retail pharmacies in the country and the pharmacist's personalized consultation and recommendations are bolstering the segment's expansion. Additionally, these pharmacies provide a wide range of healthcare products and drugs at one location, which in turn enhances consumer convenience. Various retail pharmacy chains are rapidly growing in the country by providing such advantages to customers. For instance, in September 2022, Apollo Pharmacy announced the opening of its 5000th outlet in India.

Meanwhile, online pharmacies are expected to witness significant growth over the forecast period. This growth can be attributed to the convenience, accessibility, and value-added services online pharmacies provide. They eliminate the requirement for physically visiting the store to pick up the medications, while providing overnight shipping and delivery, aiding patients in effectively managing their diseases.

Future Market Scenario (FY2025-FY2032F)

According to the India generic drugs market analysis, the market is expected to witness significant growth in the coming years owing to the rapid expansion of the healthcare sector, increasing prevalence of chronic diseases and disorders, and rising requirements for affordable healthcare solutions. As per the statistical analysis of incidence rates of cancer published in the Indian Journal of Public Health, the burden of cancer is estimated to rise to 2.98 million by 2025 in India. The ongoing investments in research and development and manufacturing activities and the introduction of supportive government policies are also expected to support the growth of the market over the forecast period. Additionally, the increasing focus of various key market players towards the introduction of generic drugs in the country is also supporting the market's expansion. Furthermore, the introduction of various technologies, including 3-D printing, to support the manufacturing of generic drugs is also propelling the share of generic medicines in the country's pharma industry.

Key Players Landscape and Outlook

The growth of the India generic drugs market is supported by the increasing investments by the key players of the market towards the launch of various generic drugs in India. In March 2024, the Zydus Group launched IBYRA, the generic version of Olaparib, which is a PARP inhibitor in India. The drug targets genetic mutations that are present in different cancer types, allowing for more effective and tailored treatment approaches. Cancer patients who have been diagnosed with BRACA and HRD-positive mutations are administered PARP inhibitors to delay the progression of the diseases. To ensure that the correct patient groups have access to IBYRA, Zydus collaborated with MedGenome Inc. for comprehensive HRD testing.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. India Generic Drugs Market Outlook, FY2018-FY2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Application
      • 4.2.1.1. Neurovascular
      • 4.2.1.2. Cardiovascular
      • 4.2.1.3. Dermatology
      • 4.2.1.4. Oncology
      • 4.2.1.5. Diabetology
      • 4.2.1.6. Respiratory
      • 4.2.1.7. Others
    • 4.2.2. By Type
      • 4.2.2.1. Biosimilar Generics
      • 4.2.2.2. Small Molecule Generics
    • 4.2.3. By Brand
      • 4.2.3.1. Branded Generic
      • 4.2.3.2. Pure Generic
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Injectable
      • 4.2.4.3. Topical
      • 4.2.4.4. Others
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Hospital Pharmacy
      • 4.2.5.2. Retail Pharmacy
      • 4.2.5.3. Online Pharmacy
    • 4.2.6. By Region
      • 4.2.6.1. North
      • 4.2.6.2. East
      • 4.2.6.3. West and Central
      • 4.2.6.4. South
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
  • 4.3. Market Map Analysis, FY2024
    • 4.3.1. By Application
    • 4.3.2. By Type
    • 4.3.3. By Brand
    • 4.3.4. By Route of Administration
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

  • 11.1. Market Drivers
  • 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

  • 13.1. Bioavailability/Bioequivalence Studies
  • 13.2. Regulatory Approvals

14. Patent Expiration

15. Case Studies

16. Competitive Landscape

  • 16.1. Competition Matrix of Top 5 Market Leaders
  • 16.2. SWOT Analysis for Top 5 Players
  • 16.3. Key Players Landscape for Top 10 Market Players
    • 16.3.1. Aurobindo Pharmaceuticals
      • 16.3.1.1. Company Details
      • 16.3.1.2. Key Management Personnel
      • 16.3.1.3. Products and Services
      • 16.3.1.4. Financials (As Reported)
      • 16.3.1.5. Key Market Focus and Geographical Presence
      • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 16.3.2. Sun Pharmaceutical Industries Ltd.
    • 16.3.3. Cipla Ltd.
    • 16.3.4. Dr. Reddy's Laboratories
    • 16.3.5. Teva Pharmaceuticals Industries Ltd.
    • 16.3.6. Lupin Ltd.
    • 16.3.7. Zydus Group
    • 16.3.8. Novartis AG
    • 16.3.9. Fresenius Kabi India Pvt. Ltd.
    • 16.3.10. Viatris Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. India Generic Drugs Market, By Value, In USD Billion, FY2018-FY2032F
  • Figure 2. India Generic Drugs Market, By Volume, In Number of Prescriptions, FY2018-FY2032F
  • Figure 3. India Generic Drugs Market Share (%), By Application, FY2018-FY2032F
  • Figure 4. India Generic Drugs Market Share (%), By Type, FY2018-FY2032F
  • Figure 5. India Generic Drugs Market Share (%), By Brand, FY2018-FY2032F
  • Figure 6. India Generic Drugs Market Share (%), By Route of Administration, FY2018-FY2032F
  • Figure 7. India Generic Drugs Market Share (%), By Distribution Channel, FY2018-FY2032F
  • Figure 8. India Generic Drugs Market Share (%), By Region, FY2018-FY2032F
  • Figure 9. By Application Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 10. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 11. By Brand Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 12. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 13. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 14. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2024